Home / Archive / October 2016

October 2016 Volume 12, Issue 10

Volume 12, Issue 10 | October 2016

October 2016

In this Issue

Q&A

Q&A: Working to deal a critical blow to brain cancer in kids

National Brain Tumor Society talks about its part in launching Project Impact and what that means to the landscape of pediatric brain tumor treatment

Business & Government Policy

Patent Docs: The Trans-Pacific Partnership--What it may mean for the pharmaceutical industry

While the treaty’s principal provisions include lower tariffs and dispute resolution mechanisms, there are several sections related to patent law relevant to the U.S. pharmaceutical industry, and Kevin Noonan explains

Determining cell death

NIH-university collaboration advances potential Zika virus treatments

French connection

Advanced Analytical establishes office in Genopole, France

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

For your approval

A collection of recent regulatory approvals and other actions globally

Feature

Show Preview: Explore the brain and nervous system at Neuroscience 2016

After visiting Chicago last year, the Society for Neuroscience brings its annual meeting to the warmer climes of Southern California

Special Reports

Special Report on Drug Metabolism: Identifying toxicity

Will embracing complexity lead to safer drugs?

Editor's Focus

A different sort of animal magnetism

Where does the target market for drugs intersect with regard to humans and animals...and should it?

Commentary

Pediatric pharmacology, part 2

Thanks to a lack of appropriate trials, pharma, healthcare professionals, government, educators, caring/hopeful parents and others are forced to wing it with drugs not fully vetted in the pediatric population

Guest Commentary: What if mice could be more like humans?

In efforts to improve upon the human relevance of mouse-based studies, investigators are increasingly turning to models with genetically introduced human components

Research & Development

Delving into drug delivery

F-star and Denali to develop multispecific antibody platform for crossing blood-brain barrier

Junk DNA and genomic stability

Duke researchers discover connection between junk DNA variations and increased risk of cancer or other diseases

Four months, four agreements

Selexis inks cell license agreement with Pieris for immuno-oncology bispecific drug candidate

Of eggs and enzymes

‘Egg unboiling’ technology could change the way enzymes are used in research

Getting to the heart of HCM

Stem-cell model of heart condition reveals how the fibrosis is perpetuated

InSphero launches 3D mitochondrial toxicity testing service

InSight Mitochondrial Toxicity Testing provides for the identification of mitochondrial liabilities during drug development and safety testing

First proposal of strategies for validating antibody specificity

The International Working Group on Antibody Validation announced recently the publication of initial strategies developed to address a critical unmet need for antibody specificity, functionality and reproducibility

Contract Services

Cinven expands clinical services footprint

Bioclinica acquisition deal marks the first investment with the Sixth Cinven Fund

Calithera selects ProTrials for early-phase trial support

Agreement provides clinical development services for Calithera’s CB-839 oncology therapeutic

Crown Bioscience boosts oncology offerings

Company expands site and services at San Diego Center of Excellence for Oncology

Charles River acquires Agilux Laboratories

M&A deal enhances Charles River’s early-stage capabilities in bioanalytical services

Clinical Trials

Sanofi shines in diabetes and dermatology

Recent study results for Toujeo and Dupixent mark two clinical trial successes this fall

Promising data for patients with Crohn’s disease

Celgene announces promising top-line data from trial of oral mongersen for both endoscopic and clinical outcomes

Oh, Canada; oh, diabetes

Sernova seeks FDA approval for U.S. clinical trial on Cell Pouch System for diabetics

Illumina software supports cancer study

Company’s technology is being brought to bear on behalf of the TAPUR Molecular Tumor Board for precision medicine cancer study

Out of the starting gate

A roundup of clinical trial startups and initial breakthroughs

Achillion announces 100-percent SVR in trial evaluating triple combination of odalasvir, AL-335 and simeprevir

Achillion Pharmaceuticals Inc. has announced that new interim results from a Phase 2a study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies, were published as part of the abstracts released for the European Association for the Study of the Liver Special Conference held Sept. 23-24 in Paris

Discovery

New understanding of cocaine addiction

Recent TSRI study findings suggest pharmacological remedies are possible

Warp speed ahead

Company gets SMART Platform patent for identifying new therapeutic agents naturally

The promise of peroxiredoxin

A protein that clears hydrogen peroxide from cells could offer new options for antibiotics

Stanford and twoXAR team up against liver cancer

Researchers to validate computationally derived drug candidates targeting hepatocellular carcinoma